Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02692872 · ClinicalTrials.gov registry record

Screening for Alpha Thalassemia in Healthy Volunteers

A clinical trial of Alpha-Thalassemia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Active
Registry status
367
Enrollment target
1
Study location

NCT02692872: Active study of Alpha-Thalassemia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT02692872 is a study of Alpha-Thalassemia that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 367 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02692872, a study of Alpha-Thalassemia, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

ACTIVE NOT RECRUITING
Registry status
367 participants
Enrollment target
1
Study location

Study Summary

Background: Alpha thalassemia is a blood disorder. It is caused by genetic deletions. Part of the DNA is missing from a group of genes called alpha globin. Alpha thalassemias are some of the most common genetic deletions. We are testing for alpha thalassemia trait. Alpha thalassemia trait is when someone has only two out of the normal four alpha globin genes. In some people, they lead to no symptoms. Others have changes that lead to disease, including mild anemia. Researchers want to learn more about alpha thalassemia and blood vessels. This may allow them to develop new treatments for blood diseases such as sickle cell disease. Objective: To better understand how alpha globin deletions in healthy people affect blood vessels. Eligibility: Healthy volunteers ages 18-39 who self-report African ancestry. Design: Participants will provide a one-time saliva sample. This can be by mail, in-person at a study event, or at NIH. Participants will get a small kit to collect their saliva sample. The kit has easy instructions. The sample does not need to be put in the refrigerator. Participants will spit a small amount of saliva (less than half a teaspoon) into a collection tube. Participants will close the funnel lid tightly, and then unscrew the funnel lid from the tube. They will then close the tube tightly with the small cap provided and shake the tube for 5 seconds. Participants will place the tube in the provided envelope and mail it to NIH. The specimen will be stored and processed in the lab. Participants may be invited to participate in more research studies, whether or not researchers find that they have alpha thalassemia trait.

Primary Outcome

As this is not a treatment protocol, there is no primary endpoint. The primary objective is to identify presence of double alpha globin deletions in healthy volunteers.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 367 participants
Start Date 2017-04-17
Est. Completion 2027-12-31

What the registry record for NCT02692872 still lists

NCT02692872 is an observational study that tracks outcomes without assigning an intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Alpha-Thalassemia appearing as the primary indexed condition, and to 0 interventions.

NCT02692872 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02692872 about?

NCT02692872 is a clinical study titled "Screening for Alpha Thalassemia in Healthy Volunteers". Background: Alpha thalassemia is a blood disorder. It is caused by genetic deletions. Part of the DNA is missing from a group of genes called alpha globin. Alpha thalassemias are some of the most common genetic deletions. We are testing for alpha thalassemia trait. Alpha thalassemia trait is when s...

What is the current status of trial NCT02692872?

This trial is currently active not recruiting. The enrollment target is 367 participants. The study started on 2017-04-17. Estimated completion is 2027-12-31.

What conditions does trial NCT02692872 study?

This clinical trial studies the following conditions: Alpha-Thalassemia.

Who is sponsoring clinical trial NCT02692872?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02692872 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alpha-Thalassemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04675476 · 368 participants · NA

    A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening

  • NCT05215353 · 368 participants · Phase 4

    A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors

  • NCT06182397 · 368 participants · NA

    Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  • NCT06629610 · 368 participants · NA

    Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02692872, the US trial registry maintained by the National Library of Medicine. NCT02692872 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.